Risks of Perinephric Fat Thickness on Adverse Renal Outcomes Post Donor Nephrectomy

Overview

About this study

The purpose of this study is to compare pro-inflammatory and pro-fibrotic cytokines expression in 40 Living kidney donors (LKDs), stratified by low PRAT thickness (<10 mm) and high PRAT thickness (>14 mm) identified on the pre-donation CT scan.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Males or females between the age of 18-80 years at the time of signing consent
  • BMI ≤27 kg/m2 or >30 kg/m2
  • Individuals must be scheduled to have a live donor kidney nephrectomy at the time of consent
  • Potential participants must have the ability to provide consent
  • CT of abdomen and pelvis done within 6 months of the screening visit
  • mGFR test completed within 6 months prior to nephrectomy.
  • The participant must have the ability to give consent or have an appropriate representative available to do so.
  • Men or women of childbearing potential must be practicing a form of contraception before signing consent and agree to maintain this method for the entirety of the study. Acceptable methods include oral contraceptives, condoms, abstinence, intrauterine devices (IUDs)

Exclusion Criteria:

  • Those who do not meet Mayo Clinic Rochester’s clinical criterion for donor nephrectomy
  • >10% weight change between the donor evaluation (screening visit) and donor nephrectomy
  • Individuals who have a BMI >27 kg/m2 but <30 kg/m2 
  • Individuals who are pregnant or are planing to become pregnant
  • Inability to comply with study procedures or any condition that, in the opinion of the investigator, could increase the patient’s risk by participating in the study or confound the outcome of the study.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 07/26/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Aleksandra Kukla, M.D.

Contact us for the latest status

Contact information:

Jacqulyn Reiter

(507) 538-2224

Reiter.Jacqulyn@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20577122

Mayo Clinic Footer